Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies

被引：53

作者：

Chartrain, Michel ^{[1
]}

Chu, Lily ^{[1
]}

机构：

[1] Merck Res Labs, Dept Bioproc R&D, Rahway, NJ 07065 USA

来源：

CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2008年 / 9卷 / 06期

关键词：

D O I：

10.2174/138920108786786367

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This article provides an overview of the upstream technologies used in the industrial production of therapeutic monoclonal antibodies (mAbs) based on the cultivation of mammalian cells. More specifically, in a first section, after a short discussion of relevant biochemical characteristics of antibodies, we review the cell lines currently employed in commercial production and the methods of constructing and isolating production clones. This is followed with a review of the most current methods of commercial scale production and their associated technologies. Selected references and short discussions pertaining to emerging and relevant technologies have been embedded throughout the text in order to give a sense of the overall direction the field is taking.

引用

页码：447 / 467

页数：21

共 199 条

[81] Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis [J].

Hendrick, V ;

Winnepenninckx, P ;

Abdelkafi, C ;

Vandeputte, O ;

Cherlet, M ;

Marique, T ;

Renemann, G ;

Loa, A ;

Kretzmer, G ;

Werenne, J .

CYTOTECHNOLOGY, 2001, 36 (1-3) :71-83

[82] Twenty-four-well plate miniature Bioreactor high-throughput system: Assessment for microbial cultivations [J].

Isett, Kevin ;

George, Hugh ;

Herber, Wayne ;

Amanullah, Ashraf .

BIOTECHNOLOGY AND BIOENGINEERING, 2007, 98 (05) :1017-1028

[83] Engineering antibodies for clinical applications [J].

Jain, Maneesh ;

Kamal, Neel ;

Batra, Surinder K. .

TRENDS IN BIOTECHNOLOGY, 2007, 25 (07) :307-316

[84] From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice [J].

Jakobovits, Aya ;

Amad, Rafael G. ;

Yang, Xiaodong ;

RoskoS, Lorin ;

Schwab, Gisela .

NATURE BIOTECHNOLOGY, 2007, 25 (10) :1134-1143

[85]

Jayme D W, 1985, Adv Biotechnol Processes, V5, P1

[86] NUTRIENT OPTIMIZATION FOR HIGH-DENSITY BIOLOGICAL PRODUCTION APPLICATIONS [J].

JAYME, DW .

CYTOTECHNOLOGY, 1991, 5 (01) :15-30

[87] Glycosylation of recombinant antibody therapeutics [J].

Jefferis, R .

BIOTECHNOLOGY PROGRESS, 2005, 21 (01) :11-16

[88]

JEFFERIS R, 2006, BIOPROCESS INT, P40

[89] High-level expression of recombinant IgG in the human cell line PER.C6 [J].

Jones, D ;

Kroos, N ;

Anema, R ;

van Montfort, B ;

Vooys, A ;

van der Kraats, S ;

van der Helm, E ;

Smits, S ;

Schouten, J ;

Brouwer, K ;

Lagerwerf, F ;

van Berkel, P ;

Opstelten, DJ ;

Logtenberg, T ;

Bout, A .

BIOTECHNOLOGY PROGRESS, 2003, 19 (01) :163-168

[90] Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC [J].

Kanda, Yutaka ;

Yamane-Ohnuki, Naoko ;

Sakai, Naoto ;

Yamano, Kazuya ;

Nakano, Ryosuke ;

Inoue, Miho ;

Misaka, Hirofurni ;

Iida, Shigeru ;

Wakitani, Masako ;

Konno, Yoshinobu ;

Yano, Keiichi ;

Shitara, Kenya ;

Hosoi, Shinji ;

Satoh, Mitsuo .

BIOTECHNOLOGY AND BIOENGINEERING, 2006, 94 (04) :680-688

← 4 5 6 7 8 9 10 11 12 13 →